Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study.

Juan M Maza-SolanoChristian Calvo-HenríquezIsam AlobidMarta Álvarez-CendreroÓscar Palomares Ramon Moreno-Luna Jaime Santos-Perez Jaime González-García Serafín Sánchez-Gómez

Published in: Journal of clinical medicine (2022)

A significant clinical response based on SNOT-22 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT-22 questionnaires.

Keyphrases

ejection fraction
lung function
cystic fibrosis
depressive symptoms
physical activity
sleep quality
monoclonal antibody
allergic rhinitis